Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

Abstract

Early treatment for patients with high-risk smoldering myeloma delays progression to active disease and increases overall survival. (Funded by Celgene; ClinicalTrials.gov number, NCT00480363.).

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

“…12 Several studies are currently exploring platforms of therapy in SMM patients. 13 We assessed the potential impact of treating 'early myeloma' using an immune-based strategy with IPH2101 in a patient cohort (n=9) that presumably had preserved NK-cell function.…”

Treatment of smoldering multiple myeloma

“…10, 554-555; 2013) 1 that focused on a recently published study by Mateos and colleagues. 2 We agree with Rajkumar and Kyle that additional studies are needed to determine the patients with SMM who would benefit from early treatment. 1 However, although treatment of a tumour at an early stage is, of course, ideal in attempting to achieve a cure, many questions arise from the underlying study 2 and we would like to raise some further points of discussion not conveyed in the recent editorial.…”

“…When comparing the SMM treatment and observation groups, a clear advantage in overall survival must be seen. 1,2 This advantage is related not only to safety and quality-of-life issues for the patient, but is also relevant in terms of understanding the cost effectiveness of treatments. Experimental treatment must be superior in terms of overall survival, either to the gold standard treatment at disease progression (for that population stratified by age), or should be the same treatment for both groups (type and duration).…”

Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults

“…25 Patients with SMM should be monitored at 2 to 3 months after the diagnosis and then every 4 to 6 months with an HP and laboratory testing. 25 There are several therapies currently under investigation to prevent or delay progression to symptomatic MM, 26 but standard of care in the United States arguably remains observation. Medical oncologists and hematologists are often involved in monitoring these higher-risk patients.…”